Trial Profile

A multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Sentagliptin combined with metformin in the treatment of patients with type 2 diabetes

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Dec 2024 According to a CGeneTech media release, company announced that National Medical Products Administration (NMPA) of China announced that Sengagliptin phosphate tablets (formerly known as saxagliptin phosphate tablets), has been approved for market in China based on the results of phase 3 study.
05 Dec 2024 Results presented in a CGeneTech Media Release.
20 Mar 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com